IBM Retirement Fund reduced its position in shares of Boston Scientific Co. (NYSE:BSX) by 7.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,991 shares of the medical equipment provider’s stock after selling 1,585 shares during the period. IBM Retirement Fund’s holdings in Boston Scientific were worth $742,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of BSX. We Are One Seven LLC purchased a new stake in shares of Boston Scientific during the fourth quarter worth about $27,000. Ipswich Investment Management Co. Inc. purchased a new stake in shares of Boston Scientific during the fourth quarter worth about $28,000. Athena Capital Advisors LLC purchased a new stake in shares of Boston Scientific during the fourth quarter worth about $28,000. CWM LLC boosted its holdings in shares of Boston Scientific by 54.3% during the fourth quarter. CWM LLC now owns 1,020 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 359 shares during the period. Finally, West Oak Capital LLC lifted its holdings in Boston Scientific by 40.0% in the fourth quarter. West Oak Capital LLC now owns 1,050 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 300 shares during the period. Institutional investors own 91.28% of the company’s stock.

In other Boston Scientific news, CFO Daniel J. Brennan sold 64,223 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $40.84, for a total transaction of $2,622,867.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Kevin J. Ballinger sold 14,740 shares of the firm’s stock in a transaction that occurred on Thursday, January 3rd. The shares were sold at an average price of $33.65, for a total transaction of $496,001.00. The disclosure for this sale can be found here. Insiders have sold 343,361 shares of company stock valued at $13,618,259 in the last ninety days. Insiders own 0.73% of the company’s stock.

Several brokerages have commented on BSX. Argus raised their price objective on shares of Boston Scientific from $43.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, February 13th. Canaccord Genuity restated a “buy” rating and issued a $45.00 price objective on shares of Boston Scientific in a report on Monday, February 11th. SunTrust Banks restated a “buy” rating and issued a $47.00 price objective on shares of Boston Scientific in a report on Friday, February 8th. Guggenheim restated a “buy” rating and issued a $48.00 price objective on shares of Boston Scientific in a report on Friday, February 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $43.00 price objective on shares of Boston Scientific in a report on Wednesday, February 6th. Three research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $40.54.

Shares of NYSE BSX opened at $40.21 on Friday. Boston Scientific Co. has a fifty-two week low of $26.27 and a fifty-two week high of $41.00. The company has a market cap of $55.73 billion, a price-to-earnings ratio of 27.35, a price-to-earnings-growth ratio of 2.30 and a beta of 0.88. The company has a quick ratio of 0.54, a current ratio of 0.76 and a debt-to-equity ratio of 0.55.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 6th. The medical equipment provider reported $0.39 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.02. Boston Scientific had a net margin of 17.01% and a return on equity of 25.92%. The business had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.57 billion. During the same quarter last year, the firm earned $0.34 earnings per share. The business’s revenue for the quarter was up 6.4% on a year-over-year basis. On average, sell-side analysts anticipate that Boston Scientific Co. will post 1.56 EPS for the current year.

WARNING: “IBM Retirement Fund Has $742,000 Stake in Boston Scientific Co. (BSX)” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/ibm-retirement-fund-has-742000-stake-in-boston-scientific-co-bsx/2896834.html.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Story: What is the yield curve?

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.